Fed. Circ. Judge Skeptical Amgen Cholesterol Drug IP Is Valid
Law360 (December 9, 2020, 7:48 PM EST) -- A Federal Circuit judge told an attorney Wednesday he faced an "uphill battle" in showing two Amgen patents on cholesterol-lowering drug Repatha are valid, casting doubt on the biopharmaceutical giant's closely watched bid to undo a district court win for its rival Sanofi.
U.S. Circuit Judge Alan D. Lourie chimed in about 20 seconds after Amgen attorney Jeffrey A. Lamken started making his argument during Wednesday's remote hearing that a Delaware federal judge wrongly overturned a jury verdict after determining the evidence didn't support Amgen's conclusion that the patent claims are enabled, meaning that a skilled artisan could make or use...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!